To counter such responses, we combined SC144@HABN with anti-PD-L1 therapy, leading to amplification of anti-tumor CD8+ T-cell responses with robust anti-tumor efficacy in both MC38 and 4T1 tumor models (Figs. 4, 5). Here, CD8A is linked to neoplasm.